布地奈德雾化混悬剂联合鼠神经生长因子治疗感冒后嗅觉障碍  

Budesonide nebulizing suspension combined with nerve growth factor for the treatment of olfactory dysfunction following viral infection of the upper respiratory tract

作　　者：刘剑锋[1] 韩红蕾[1] 王蓓[2] 庞春红[2] 杨大章[1] 王剑[3] 倪道凤[3] 

机构地区：[1]中日友好医院耳鼻咽喉科,北京100029 [2]中日友好医院病理科 [3]中国医学科学院北京协和医院耳鼻咽喉科

出　　处：《临床耳鼻咽喉头颈外科杂志》2015年第20期1787-1789,共3页Journal of Clinical Otorhinolaryngology Head And Neck Surgery

基　　金：国家自然基金(No:30801281;81300816);人社部留学人员科技活动择优资助项目(No:013-QTL-026);中日友好医院青年科技英才计划(No:2014-QNYC-A-02)

摘　　要：目的:研究联合应用糖皮质激素和鼠神经生长因子治疗感冒后嗅觉障碍的疗效。方法:12例感冒后嗅觉障碍的患者纳入研究。行T&T主观嗅觉测试,鼻窦CT扫描,嗅神经薄层扫描。联合应用布地奈德雾化混悬液雾化吸入(2mg,每日1次,2周后减为1mg)和注射用鼠神经生长因子(30μg,每日1次)肌内注射,疗程4周。共10例完成治疗方案。治疗结束后复查T&T主观嗅觉测试。结果:治疗后T&T平均嗅觉识别阈值较治疗前显著下降(分别为2.96和5.32,P<0.01)。3例嗅觉减退患者均治愈;7例嗅觉完全缺失患者中,明显改善4例,改善3例。无明显不良反应。结论:初步研究显示糖皮质激素雾化吸入联合鼠神经生长因子能安全有效地治疗感冒后嗅觉障碍。Objective：To investigate the efficacy and safety of budesonide nebulizing suspension combined with nerve growth factor in the treatment of olfactory dysfunction following viral infection of the upper respiratory tract. Method：Twelve patients with olfactory dysfunction following viral infection of the upper respiratory tract were recruited in current study. All of them underwent T＆T olfactory testing, sinonasal computer tomgraphy scanning, as well as magnetic resonance scanning of the olfactory pathway. Budesonide nebulizing suspension was inhaled once daily at the starting dose of 2 mg tapered to 1 mg after two weeks combined with mouse nerve growth factor for injection administered at a dose of 30 μg once daily for four weeks. T＆T olfactory testing were repeated after four-week treatment. Result：Ten of twelve patients received entire treatment. Seven patients were anosmia, two moderate hyposmia with parosmia, one profound hyposmia with phantosmia. After teatment, complete recov- ery were achieved in three patients with hyposmia; remarkable improvement and improvement were achieved in four and three patients with anosmia. T＆T olfactory discrimination score decreased after treatment （5.32 vs 2.96）. No side effect was found. Conclusion：The primmary outcomes suggest the efficacy and safety of nebulized glucocortoeoid combined with nerve growth factor in treatment of postviral olfactory dysfunction.

关 键 词：嗅觉障碍 感冒 糖皮质激素 神经生长因子 

分 类 号：R765.6[医药卫生—耳鼻咽喉科]